国新健康
(000503)
| 流通市值：65.61亿 | | | 总市值：65.61亿 |
| 流通股本：9.79亿 | | | 总股本：9.79亿 |
| 报告期 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 101,543,897.09 | 50,520,618.6 | 350,444,166.57 | 170,401,734.11 |
| 营业收入 | 101,543,897.09 | 50,520,618.6 | 350,444,166.57 | 170,401,734.11 |
| 二、营业总成本 | 206,596,943.51 | 103,573,911.28 | 502,143,782.43 | 323,277,664.25 |
| 营业成本 | 116,338,876.3 | 58,607,093.86 | 276,111,254.92 | 179,182,098.76 |
| 税金及附加 | 640,589.41 | 234,699.99 | 2,012,626.97 | 842,561.9 |
| 销售费用 | 34,076,282.94 | 16,134,227.86 | 80,872,793.46 | 50,376,899.05 |
| 管理费用 | 48,723,619.34 | 25,263,927.39 | 130,960,106.96 | 84,772,819.82 |
| 研发费用 | 702,434.09 | 434,943.11 | 2,799,146.34 | 1,568,783.86 |
| 财务费用 | 6,115,141.43 | 2,899,019.07 | 9,387,853.78 | 6,534,500.86 |
| 其中:利息费用 | 6,167,157.65 | 2,952,037.25 | 10,872,718.34 | 7,770,877.02 |
| 其中:利息收入 | 250,203.8 | 171,557.55 | 1,953,990.24 | 1,531,369.06 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | 0 | - | -260,920,000 | - |
| 加:投资收益 | 8,385,830.81 | 2,735,581.07 | 24,054,387.69 | 16,565,620.64 |
| 资产处置收益 | 11,987.5 | - | -49,277.13 | -10,565.71 |
| 资产减值损失(新) | 292,084.7 | 437,584.13 | 4,405,725.03 | 3,485,663.04 |
| 信用减值损失(新) | -5,854,474.34 | 1,176,099.45 | -18,874,117.29 | -5,331,635.44 |
| 其他收益 | 158,209.83 | 99,594.3 | 487,379.59 | 428,784.1 |
| 四、营业利润 | -102,059,407.92 | -48,604,433.73 | -402,595,517.97 | -137,738,063.51 |
| 加:营业外收入 | 25,003.46 | 1.03 | 215,290.45 | 57,806.21 |
| 减:营业外支出 | 35,900.24 | 28,042.23 | 1,539,419.71 | 313,904.45 |
| 五、利润总额 | -102,070,304.7 | -48,632,474.93 | -403,919,647.23 | -137,994,161.75 |
| 减:所得税费用 | 198,687.98 | - | 73,912.79 | 435,142.9 |
| 六、净利润 | -102,268,992.68 | -48,632,474.93 | -403,993,560.02 | -138,429,304.65 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | -102,268,992.68 | -48,632,474.93 | -403,993,560.02 | -138,429,304.65 |
| 终止经营净利润 | - | - | 0 | - |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | -102,268,992.68 | -48,632,474.93 | -403,993,560.02 | -138,429,304.65 |
| 少数股东损益 | 0 | - | - | - |
| 扣除非经常损益后的净利润 | -102,071,230.53 | -48,609,633.73 | -141,627,317.48 | -138,186,108.39 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | -0.1 | -0.05 | -0.41 | -0.14 |
| (二)稀释每股收益 | -0.1 | -0.05 | -0.41 | -0.14 |
| 八、其他综合收益 | -132,540.76 | -67,439.93 | 6,255,694.96 | -152,869.38 |
| 归属于母公司股东的其他综合收益 | -132,540.76 | -67,439.93 | 6,255,694.96 | -152,869.38 |
| 九、综合收益总额 | -102,401,533.44 | -48,699,914.86 | -397,737,865.06 | -138,582,174.03 |
| 归属于母公司股东的综合收益总额 | -102,401,533.44 | -48,699,914.86 | -397,737,865.06 | -138,582,174.03 |
| 归属于少数股东的综合收益总额 | - | - | - | 0 |
| 公告日期 | 2026-08-26 | 2026-04-29 | 2026-04-29 | 2025-10-30 |
| 审计意见(境内) | | | 标准无保留意见 | |